Genetronics to Introduce Its Electroporation Therapy at Major European Oral Cancer Conference

Apr 23, 2001, 01:00 ET from Genetronics Biomedical Ltd.

    SAN DIEGO and THE HAGUE, Netherlands, April 23 /PRNewswire Interactive
 News Release/ -- Genetronics Biomedical Ltd. (Amex:   GEB; Toronto) today
 announced that it will introduce its MedPulser(TM) Electroporation Therapy
 System at the 7th International Congress on Oral Cancer (ICOOC) in the
 Netherlands on April 23, 2001.  Genetronics is also a principal sponsor of the
 event, which annually brings together the top physicians in otolaryngology.
     "The ICOOC is an outstanding opportunity to introduce our CE Marked
 MedPulser(TM) Electroporation Therapy System to the leading authorities in
 head and neck surgery in Europe," said Babak Nemati, Ph.D., Genetronics
 Vice-President for Corporate Development.  "This Congress marks the beginning
 of our marketing efforts in Europe, where our Electroporation Therapy System
 is approved for sale and use in patients."
     Electroporation involves the use of extremely brief, intense, pulsed
 electric fields to temporarily permeabilize cell membranes, creating transient
 pores, which allow the entry of anti-cancer drugs directly into the cancer
 cell where the drug is more effective.  Electroporation Therapy (EPT) can
 potentially represent a tissue-preserving alternative to surgical resection,
 and offers the potential advantages of significantly shorter hospital stay,
 improved quality of life following treatment, and efficacy in patients
 refractory to standard of care therapies.
     At the ICOOC conference, Genetronics will introduce physicians to EPT
 through oral presentations and booth exhibits, demonstrating the device and
 its significant benefits compared to other treatment options.  "The feedback
 we receive from this key target audience will help us to refine our sales
 strategy," said Dr. Nemati.  Genetronics will also conduct a satellite panel
 presentation during the conference showcasing the clinical experience to date
 with EPT for the treatment of head and neck cancers in major European and U.S.
 hospitals.
     The panel presentations will be chaired by Dr. Nemati and will include
 talks by Professor Martin Burian of University of Vienna, Vienna, Austria, Dr.
 Thomas Plath, of the Benjamin Franklin Medical Center, Berlin, Germany, Dr.
 William R. Panje, M.D., F.A.C.S., of Rush-Presbyterian-St. Luke's Medical
 Center, Chicago, IL, one of the pioneers in the use of EPT, and Dr. Gerard
 Seroussi, M.D., discussing the clinical trials experience to date in France.
 
     Genetronics Biomedical Ltd. operates through its wholly owned San Diego
 subsidiary, Genetronics, Inc.  Founded in 1983, Genetronics, Inc., specializes
 in targeted intracellular delivery of large-molecule therapeutics.
 Concentrating on oncology and gene therapy, Genetronics is developing its
 proprietary platform technology, Electroporation Therapy (EPT), with the aim
 of enhancing patients' quality of life and providing safe, effective and
 comparatively low-cost treatment.  In the field of oncology, development
 programs focus on diseases with high unmet need, including cancers of the head
 and neck, liver, pancreas and skin.  Genetronics BTX(R) Instrument Division, a
 leader in molecular delivery, featuring electroporation and electrofusion
 technology for the research laboratory, markets an extensive line of products
 for in vitro, ex vivo, and animal in vivo applications worldwide.  More
 information can be found at www.genetronics.com.
 
     This press release contains certain forward-looking statements relating to
 the Company's plans to develop its electroporation drug delivery system, and
 its corporate financing activities.  The availability of resources to support
 operations and plans for obtaining additional financing cannot be assured.
 Actual events or results may differ from the Company's expectations as a
 result of a number of factors, including the uncertainties inherent in
 clinical trials and product development programs, evaluation of potential
 opportunities, the level of corporate expenditures, capital market conditions,
 and others set forth in the Genetronics Annual Report, on Form 10-K and other
 regulatory filings.  There can be no assurance that any product in Genetronics
 product pipeline will be successfully developed or manufactured, or that final
 results of human pilot studies or clinical studies will be supportive of
 regulatory approvals required to market products.  The American and Toronto
 Stock Exchanges have not reviewed and do not accept responsibility for the
 adequacy or accuracy of this release.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X32722006
 
 

SOURCE Genetronics Biomedical Ltd.
    SAN DIEGO and THE HAGUE, Netherlands, April 23 /PRNewswire Interactive
 News Release/ -- Genetronics Biomedical Ltd. (Amex:   GEB; Toronto) today
 announced that it will introduce its MedPulser(TM) Electroporation Therapy
 System at the 7th International Congress on Oral Cancer (ICOOC) in the
 Netherlands on April 23, 2001.  Genetronics is also a principal sponsor of the
 event, which annually brings together the top physicians in otolaryngology.
     "The ICOOC is an outstanding opportunity to introduce our CE Marked
 MedPulser(TM) Electroporation Therapy System to the leading authorities in
 head and neck surgery in Europe," said Babak Nemati, Ph.D., Genetronics
 Vice-President for Corporate Development.  "This Congress marks the beginning
 of our marketing efforts in Europe, where our Electroporation Therapy System
 is approved for sale and use in patients."
     Electroporation involves the use of extremely brief, intense, pulsed
 electric fields to temporarily permeabilize cell membranes, creating transient
 pores, which allow the entry of anti-cancer drugs directly into the cancer
 cell where the drug is more effective.  Electroporation Therapy (EPT) can
 potentially represent a tissue-preserving alternative to surgical resection,
 and offers the potential advantages of significantly shorter hospital stay,
 improved quality of life following treatment, and efficacy in patients
 refractory to standard of care therapies.
     At the ICOOC conference, Genetronics will introduce physicians to EPT
 through oral presentations and booth exhibits, demonstrating the device and
 its significant benefits compared to other treatment options.  "The feedback
 we receive from this key target audience will help us to refine our sales
 strategy," said Dr. Nemati.  Genetronics will also conduct a satellite panel
 presentation during the conference showcasing the clinical experience to date
 with EPT for the treatment of head and neck cancers in major European and U.S.
 hospitals.
     The panel presentations will be chaired by Dr. Nemati and will include
 talks by Professor Martin Burian of University of Vienna, Vienna, Austria, Dr.
 Thomas Plath, of the Benjamin Franklin Medical Center, Berlin, Germany, Dr.
 William R. Panje, M.D., F.A.C.S., of Rush-Presbyterian-St. Luke's Medical
 Center, Chicago, IL, one of the pioneers in the use of EPT, and Dr. Gerard
 Seroussi, M.D., discussing the clinical trials experience to date in France.
 
     Genetronics Biomedical Ltd. operates through its wholly owned San Diego
 subsidiary, Genetronics, Inc.  Founded in 1983, Genetronics, Inc., specializes
 in targeted intracellular delivery of large-molecule therapeutics.
 Concentrating on oncology and gene therapy, Genetronics is developing its
 proprietary platform technology, Electroporation Therapy (EPT), with the aim
 of enhancing patients' quality of life and providing safe, effective and
 comparatively low-cost treatment.  In the field of oncology, development
 programs focus on diseases with high unmet need, including cancers of the head
 and neck, liver, pancreas and skin.  Genetronics BTX(R) Instrument Division, a
 leader in molecular delivery, featuring electroporation and electrofusion
 technology for the research laboratory, markets an extensive line of products
 for in vitro, ex vivo, and animal in vivo applications worldwide.  More
 information can be found at www.genetronics.com.
 
     This press release contains certain forward-looking statements relating to
 the Company's plans to develop its electroporation drug delivery system, and
 its corporate financing activities.  The availability of resources to support
 operations and plans for obtaining additional financing cannot be assured.
 Actual events or results may differ from the Company's expectations as a
 result of a number of factors, including the uncertainties inherent in
 clinical trials and product development programs, evaluation of potential
 opportunities, the level of corporate expenditures, capital market conditions,
 and others set forth in the Genetronics Annual Report, on Form 10-K and other
 regulatory filings.  There can be no assurance that any product in Genetronics
 product pipeline will be successfully developed or manufactured, or that final
 results of human pilot studies or clinical studies will be supportive of
 regulatory approvals required to market products.  The American and Toronto
 Stock Exchanges have not reviewed and do not accept responsibility for the
 adequacy or accuracy of this release.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X32722006
 
 SOURCE  Genetronics Biomedical Ltd.